Lates News

Novo Nordisk (NVO.N) announced that the long-term weight management indication for Wegovy (semaglutide injection) has received an updated approval from China's National Medical Products Administration (NMPA), further covering the population that meets China's criteria for overweight and obesity in adults. Following this update, Wegovy is indicated for long-term weight management in adult patients, as an adjunct to a reduced-calorie diet and increased physical activity, with an initial body mass index (BMI) meeting the following conditions: 28 kg/m2 (obesity); or 24 kg/m2 to